Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer

被引：61

作者：

Albrethsen, Jakob ^{[1
]}

Moller, Christian H.

Olsen, Jesper

Raskov, Hans

Gammeltoft, Steen

机构：

[1] Glostrup Cty Hosp, Dept Clin Biochem, DK-2600 Glostrup, Denmark

[2] Gentofte Univ Hosp, Dept Surg, DK-2900 Hellerup, Denmark

[3] Gentofte Univ Hosp, Dept Gastrosurg, DK-2900 Glostrup, Denmark

[4] Colotech Ltd, DK-2100 Copenhagen O, Denmark

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 17期

关键词：

colorectal cancer; diagnosis; protein marker; HNP; 1-3; HUMAN NEUTROPHIL PEPTIDE-1; ALPHA-DEFENSINS; EPITHELIAL-CELLS; IDENTIFICATION; EXPRESSION; COLON; CARCINOMA; BIOMARKER; ANTIGEN; DISEASE;

D O I：

10.1016/j.ejca.2006.05.039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Colorectal cancer (CRC) patients have increased levels of human neutrophil peptides 1-3 (HNP1-3) in tumour tissue and plasma. The aim is to study whether the amount of HNP1-3 in tumour and plasma from CRC patients correlate with Dukes' stages A-D. The amount of HNP1-3 in tumour tissue, normal colonic mucosa, and plasma was determined with mass spectrometry. Plasma levels of HNP1-3 were determined with enzyme-linked immuno-sorbent assay (ELISA). The amount of HNP1-3 determined with mass spectrometry was increased in tumours compared to normal colonic tissue in CRC patients in Dukes' stage A-D, whereas HNP1-3 in plasma was only elevated in Dukes' stage D compared to healthy individuals. HNP1-3 plasma concentration determined with ELISA was increased in Dukes' stages C and D, but not in A and B. It is concluded that HNP1-3 is a potential marker for prognostic assessment, surveillance of patients, and monitoring chemotherapy in CRC patients with advanced disease.

引用

页码：3057 / 3064

页数：8

共 27 条

[1]

Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study [J].

Albrethsen, J ;

Bogebo, R ;

Gammeltoft, S ;

Olsen, J ;

Winther, B ;

Raskov, H .

BMC CANCER, 2005, 5 (1)

[2]

High concentrations of α-defensins in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome [J].

Ashitani, J ;

Mukae, H ;

Arimura, Y ;

Sano, A ;

Tokojima, M ;

Nakazato, M .

LIFE SCIENCES, 2004, 75 (09) :1123-1134

[3]

THE LEVELS AND BIOLOGIC ACTION OF THE HUMAN NEUTROPHIL GRANULE PEPTIDE HP-1 IN LUNG-TUMORS [J].

BATEMAN, A ;

SINGH, A ;

JOTHY, S ;

FRASER, R ;

ESCH, F ;

SOLOMON, S .

PEPTIDES, 1992, 13 (01) :133-139

[4]

Buechler KF, 2001, CLIN CHEM, V47, P144

[5]

Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease [J].

Cunliffe, RN ;

Rose, FRAJ ;

Keyte, J ;

Abberley, L ;

Chan, WC ;

Mahida, YR .

GUT, 2001, 48 (02) :176-185

[6]

Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa [J].

Cunliffe, RN ;

Kamal, M ;

Rose, FRAJ ;

James, PD ;

Mahida, YR .

JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :298-304

[7]

α-Defensins in the gastrointestinal tract [J].

Cunliffe, RN .

MOLECULAR IMMUNOLOGY, 2003, 40 (07) :463-467

[8]

Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline [J].

Desch, CE ;

Benson, A ;

Somerfield, MR ;

Flynn, PJ ;

Krause, C ;

Loprinzi, CL ;

Minsky, BD ;

Pfister, DG ;

Virgo, KS ;

Petrelli, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8512-8519

[9]

Duffy MJ, 2001, CLIN CHEM, V47, P624

[10]

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines [J].

Duffy, MJ ;

van Dalen, A ;

Haglund, C ;

Hansson, L ;

Klapdor, R ;

Lamerz, R ;

Nilsson, O ;

Sturgeon, C ;

Topolcan, O .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :718-727

← 1 2 3 →